Study on Cyclin D1 and p53 in Breast Cancer
Author Information
Author(s): R Michalides, P Hageman, H van Tinteren, L Houben, E Wientjens, R Klompmaker, J Peterse
Primary Institution: The Netherlands Cancer Institute
Hypothesis
What is the pathological relevance of cyclin D1 overexpression in human breast cancer?
Conclusion
Overexpression of cyclin D1 and p53 was not found to be of prognostic value in operable breast cancer patients.
Supporting Evidence
- Overexpression of cyclin D1 was found in 34% of breast cancer cases.
- Overexpression of p53 was found in 18% of breast cancer cases.
- Overexpression of cyclin D1 was associated with estrogen receptor-positive tumors.
- Overexpression of p53 was associated with poorly differentiated tumor types.
Takeaway
This study looked at breast cancer patients to see if certain proteins, cyclin D1 and p53, could help predict how well they would do. It turns out, they didn't really help with that.
Methodology
The study involved immunohistochemical analysis of tumor samples from 248 patients with operable breast cancer, assessing the overexpression of cyclin D1 and p53.
Potential Biases
Potential bias due to the selection of patients who were operable and did not have distant metastasis.
Limitations
The study was limited to operable breast cancer patients and may not apply to more advanced cases.
Participant Demographics
Patients were treated at the Netherlands Cancer Institute between 1974 and 1982, with a median follow-up of 106 months.
Statistical Information
P-Value
0.049
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website